Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
These bifunctional chelators are useful for radiolabeling targeting moieties with SPECT and PET radioisotopes for molecular imaging for diagnosis and/or treatment of cancer. More
Hexabrix, the contrast material used in the study thus far, has also proven to be effective for atopic dermatitis/eczema in a mouse model and for allergic conjunctivitis in a rat model. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Aug 2011 - 7 pages - $75
Nov 2011 - 6 pages - $75
Nov 2011 - 8 pages - $75
Dec 2010 - 95 pages - $3,500
Jun 2007 - 11 pages - $1,100
Nov 2011 - 6 pages - $75
Nov 2011 - 9 pages - $75
Aug 2010 - 104 pages - $3,500
Jun 2010 - 127 pages - $2,500
Jun 2010 - 126 pages - $2,500
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us